Form 4: Neuronetics Director Megan Rosengarten Receives RSU Grant

Director Megan Rosengarten was granted 30,000 restricted stock units by Neuronetics, Inc. as part of an equity award.

Summary

• Director Megan Rosengarten acquired 30,000 restricted stock units (RSUs) on May 28, 2026.
• The grant represents a contingent right to receive one share of common stock per RSU.
• Following this transaction, the director's total beneficial ownership of common stock is 170,890 shares.
• The RSUs are subject to a vesting schedule tied to service or specific corporate events.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation with no material impact on the company's operational or financial trajectory.

Positives

• Alignment of director interests with shareholders through equity-based compensation.
• Increased total beneficial ownership for a member of the Board of Directors.

Negatives

• Potential future dilution for existing shareholders upon the eventual vesting and issuance of the underlying common stock.

Risks

• Vesting is contingent upon continuous service, which could be impacted by unforeseen changes in board composition.

Future Outlook

The RSUs vest on May 28, 2027, or earlier in the event of a board-approved separation of service or a change in control of the company, provided the director maintains continuous service.

Industry Context

StockSavvy.ai notes that equity grants to directors are standard corporate governance practice in the medical device sector to ensure long-term alignment between board members and shareholders.

Comparison to Industry Standards

• The use of RSU grants for board compensation is consistent with standard practices for mid-cap medical technology companies.
• The vesting period of one year is typical for annual director equity refresh cycles.

Stakeholder Impact

• Shareholders: Minor dilution impact upon vesting.
• Director: Increased equity stake in the company.

Next Steps

• Vesting of the 30,000 RSUs on May 28, 2027, subject to continued service.

Key Dates

Keywords

Neuronetics, STIM, Form 4, Insider Trading, Director Compensation, Equity Grant